CLINICAL_TRIALS
trial_result
· 2015-07-27
Clinical Trial Update: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Summary
Phase 2 clinical trial evaluating blinatumomab in relapsed/refractory diffuse large B-cell lymphoma has completed and results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen Research (Munich) GmbH | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-07-27